Oxcarbazepine Tablet, Film Coated
Product Images NDC 70518-3237

8 FDA label images from Remedyrepack Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 70518-3237). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure diagram of the active ingredient Oxcarbazepine, showing its molecular framework including two benzene rings and functional groups characteristic of this compound.*
FDA Label Image

Figure1 (Figure1)

Figure1 (Figure1)
A Kaplan-Meier survival plot comparing Oxcarbazepine and placebo treatment groups over time from Day 2 to Day 9. The graph shows exit ratios on the vertical axis, with Oxcarbazepine represented by a solid line and placebo by a dashed line. The plot includes a log-rank test p-value of 0.0001, indicating statistical analysis between the two groups.*
FDA Label Image

Figure2 (Figure2)

Figure2 (Figure2)
A Kaplan-Meier curve comparing seizure rate over time (days from first dose to first seizure) between Oxcarbazepine and placebo groups. The x-axis represents treatment duration in days up to 140, and the y-axis shows seizure rate from 0.0 to 1.0. The graph includes a log-rank test p-value of 0.046 indicating statistical analysis of the difference between groups.*
FDA Label Image

Figure3 (Figure3)

Figure3 (Figure3)
A Kaplan-Meier survival curve showing exit rate over time (days) for two treatment groups labeled as 'High' and 'Low'. The graph includes a log-rank test p-value indicating statistical comparison between the groups.*
FDA Label Image

Figure4 (Figure4)

Figure4 (Figure4)
A Kaplan-Meier survival curve graph displaying the exit rate over time in days for two treatment groups labeled HIGH and LOW. The x-axis represents time to exit in days, and the y-axis represents the exit rate. The LOW group shows a higher and quicker exit rate compared to the HIGH group, with a log-rank test p-value of 0.0001 noted on the graph.*
FDA Label Image

Mm1 (Oxcarbazepine 300mg 70518 3237 00)

Mm1 (Oxcarbazepine 300mg 70518 3237 00)
Label for Oxcarbazepine 300 mg oral film-coated tablets, 100 count per box. The label shows dosage strength, quantity, NDC number 70518-3237-00, repackaged by RemedyRepack Inc., Indiana, PA. Storage instructions and usual dosage directions noted to see insert. Manufacturer listed as Glenmark, Mahwah, NJ.*
FDA Label Image

Mm2 (Oxcarbazepine 300mg 70518 3237 01)

Mm2 (Oxcarbazepine 300mg 70518 3237 01)
Oxcarbazepine 300 mg oral tablet, film-coated, single count packaging label. The label includes the product name, strength, dosage form, and quantity. It is repackaged by RemedyRepack Inc. and manufactured by Glenmark, Mahwah, NJ. Additional details include storage instructions and a QR code.*
FDA Label Image

Mm3 (Oxcarbazepine 300mg 70518 3237 02)

Mm3 (Oxcarbazepine 300mg 70518 3237 02)
Oxcarbazepine 300 mg tablet label for a bottle containing 30 tablets. The film-coated oral tablets are labeled with NDC 70518-3237-02 and repackaged by RemedyRepack Inc., Indiana, PA. Storage instructions and usual dosage notes are included along with a QR code.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.